Drug safety under review: study scans patient records for rare reactions
NCT ID NCT06565078
Summary
This study aims to check the safety of an existing treatment called Cuvitru in people with primary immunodeficiency (PID). Researchers will look back at the medical records of about 100 patients in Japan to see if they experienced specific, serious side effects. The goal is to gather more real-world safety information on this already approved therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.